SMOKING AND HEALTH
As many as 200,000 of the 435,000 annual deaths from smoking in the United States occur among persons with mental illness and/or substance abuse (Mauer, 2006; Schroeder, 2007b; . This high toll from tobacco use reflects the high smoking prevalence in these conditions (Lasser et al., 2000) , the fact that these smokers often consume more cigarettes than the average smoker (Lasser et al., 2000) , and the reality that about half of smokers die early from their addiction, losing up from 10 to 15 years of life expectancy (Fiore et al., 2008) . Recently, a review of death rates among patients treated at mental health clinics found that people with chronic mental illness die on average 25 years earlier than the general population (Colton & Manderscheid, 2006; Mauer, 2006) . The bulk of these deaths are not related to their intrinsic psychiatric condition but reflect mainly cardiovascular disease, diabetes, and other illnesses exacerbated by smoking. The enormity of this illness burden and the increasing recognition of the hazards of secondhand smoke exposure have broken through the traditional resistance of the mental health treatment community to address tobacco addiction (Williams, 2008) .
Other burdens of smoking in this population include the additional stigma that smoking adds to the stigma of mental illness (Christakis & Fowler, 2008; Schroeder, 2008) , as well as the financial costs of purchasing cigarettes, which can consume more than a quarter of the budget of those on public assistance (Mechanic, Blider, & McAlpine, 2002; Steinberg, Williams, & Ziedonis, 2004) .
SMOKING IS MORE COMMON AMONG PATIENTS WITH MENTAL ILLNESS AND/OR SUBSTANCE ABUSE
As I reviewed recently in the Journal of American Medical Association (Schroeder, in press) , smoking is much more common among patients with mental illness and/or substance abuse disorders than among the general population. Reported smoking prevalence ranges from 50% to 80% among patients with different categories of mental illness, with rates generally higher in the more severe mental illnesses such as schizophrenia (Grant, Hasin, Chou, Stinson, & Dawson, 2004; Kalman, Morissette, & George, 2005; Lasser et al., 2000) . In contrast, the rate in the general population has declined to a modern low of 19.8% (Centers for Disease Control and Prevention, 2008) , which would be even lower if it excluded people with mental illness and/or substance abuse disorders. Despite constituting only 22% of the population, people with mental illness (including substance abuse disorder) consume 44% (Lasser et al.,
WHY THE HIGH VULNERABILITY TO TOBACCO ADDICTION?
Reasons for these high rates of smoking include genetic susceptibility to the dopaminergic effects of nicotine exposure, relief of psychiatric symptoms, the protobacco culture of mental health treatment facilities, and the historical reluctance of mental health clinicians to address tobacco addiction as a treatable illness (Schroeder, in press) .
Regarding genetics, tobacco use and dependence is highly heritable, and there exist specific genetic patterns that link smoking and mental illness (Benowitz, 2008; Dierker, Avenevoli, Merikangas, Flaherty, & Stolar, 2001; McCaffery, Niaura, Swan, & Carmelli, 2003) . Genes that change central nervous dopamine function and transmission may also reinforce smoking, as well as influence the risk of tobacco dependence and relapse (Lerman et al., 1998) .
Biological factors may also contribute to the high rates of smoking in mental illness. Nicotine-mediated dopamine release may alleviate some schizophrenic symptoms (Ziedonis, Kosten, Glazer, & Frances, 1994) , and other chemicals in cigarette smoke reduce depression symptoms through their action on monoamine oxidase enzymes (Benowitz, 2008; Fowler et al., 1996) . Nicotine's arousal effect might also help to counter the sedating effective of many psychotropic medications (Benowitz, 2008) . Last, tobacco users who quit may experience higher levels of antipsychotic medications and some antidepressants because nicotine has stimulated the P450 hepatic enzyme system that catabolizes these drugs. Absent the nicotine, drug levels increase and the patients can mistakenly misconstrue the negative symptoms from these elevated drug levels as nicotine withdrawal.
Cultural factors also influence smoking behavior. In the past, smoking was tightly integrated into mental health treatment facilities, with access to cigarette breaks used as rewards and punishment, and cigarettes bartered for sexual favors and other commodities (Reilly, Murphy, & Alderton, 2006; Williams, 2008; . Another cultural factor is the misconception that quitting smoking would make it more difficult to treat the underlying mental illness. Recent experience with creating smoke-free mental health treatment facilities has shown that, rather than exacerbating episodes of violence and other acting out behaviors, going smoke free led to improved patient behaviors and left more time for clinical encounters with patients (Burke, 2006) . Finally, a recent survey from the Association of American of Medical Colleges documented that psychiatrists perform less well than other medical specialties in directing smokers into treatment (American Association of Medical Colleges, 2007) .
CLINICIANS MAY NOT KNOW ALL THE OPTIONS TO HELP SMOKERS QUIT
Treatment of smokers with mental illness and/or substance use disorders is similar to treatment of the general population. Although much of the literature on cessation is based on smokers without mental illness, there are sufficient studies of cessation trials in people with mental illness to warrant recommendations for treatment. A recent update of the Public Health Service Guideline for Treating Tobacco Use and Dependence has summarized the evidence for smoking cessation services (Fiore et al., 2008) . In brief, there are three major ways that clinicians can help smokers quit. First, if treatment facilities exist within their system, such as occurs in the Mayo Clinic or Kaiser Permanente of Northern California, internal referral is an option. For most facilities, however, that is not the case. The second option is to refer to toll-free telephone quitlines, which exist in every state and may be accessed by dialing 1-800-QUIT NOW. Reports from many states attest that a large proportion of callers have coexistent mental illness (Bjornson, 2008) . Efforts are accelerating within the 50 states to train counselors to effectively treat patients with mental illness and substance abuse disorders. A new version of the Rx for Change smoking cessation curriculum is now available for use by mental health peers or counselors (The Regents of the University of California, 2007). Third, mental health professionals can themselves treat patients by combining counseling with one or more of the seven available forms of evidence-based pharmacotherapy: nicotine replacement (patch, gum, lozenge, nasal spray, or inhaler); the antidepressant bupropion, which also suppresses nicotine craving; and varenicline, a new partial nicotine agonist that reduces the pleasurable aspect of nicotine inhalation and also reduces craving (Fiore et al., 2008; Schroeder & Sox, 2006) . Because smokers with mental illness are likely to smoke more and to have more severe withdrawal symptoms, they may require higher doses of medications and counseling, as well as longer duration of treatment (Schroeder, in press ).
UNCERTAIN SAFETY OF USING VARENICLINE FOR PATIENTS WITH MENTAL ILLNESS
Varenicline has been on the market for 2 years, and more than 7 million prescriptions have been filled. But its precise safety in patients with mental illness has yet to be confirmed. The original drug trials that demonstrated varenicline's effect in smoking cessation specifically excluded patients with mental illness (Gonzales et al., 2006; Jorenby et al., 2006; Schroeder, in press ). Anecdotally, a great deal of off-label use has occurred in this population, and as was recently reviewed, a number of reports of adverse neuropsychiatric events including suicidal thoughts and actual suicide have occurred in patients using varenicline (Hays & Ebbert, 2008) . Because these events are also associated with nicotine withdrawal and with underlying mental illness, it is difficult to assess the degree of causality. At present, the Food and Drug Administration has asked Pfizer, the manufacturer of varenicline (Chantix), to include a warning in its package insert. Interestingly, a similar warning also exists for bupropion, the other nonnicotine Food and Drug Administration-approved smoking cessation medication. Pfizer is conducting therapeutic trials of varenicline in patients with mental illness, and it is hoped that the results will be available within the next year or two. My recommendation is to first try other drugs for smoking cessation. If these fail, then the clinician will have to weigh the very real risks of continuing to smoke against the yet uncertain risk of using varenicline.
DO PATIENTS WITH MENTAL ILLNESS WANT TO STOP SMOKING?
It has long been contended that patients with mental illness do not want to quit smoking. But the evidence shows that about 70% want to quit, a figure comparable to the general population (Centers for Disease Control and Prevention, 2002; Fiore et al., 2008; Lucksted, McGuire, Postrado, Kreyenbuhl, & Dixon, 2004; J. J. Prochaska et al., 2004; Tsoh & Hall, 2004) . Although quit rates may be somewhat lower than for smokers without mental illness, some studies have shown 12-month cessation rates of more than 20% for patients with major depression, for example, which is comparable to studies of patients without mental illness (Brown et al., 2001 (Brown et al., , 2007 .
DOES SMOKING CESSATION EXACERBATE MENTAL ILLNESS?
Although many mental health clinicians worry that stopping smoking will exacerbate the underlying mental illness, the evidence that this occurs is surprisingly weak (Schroeder, in press; Williams, 2008) . Several factors make it difficult to tell whether cessation does make symptoms worse. First, nicotine withdrawal can mimic the symptoms of depression (Paperwalla, Levin, Weiner, & Saravay, 2004; Sánchez-Villegas et al., 2008) . Second, mental illness typically waxes and wanes, making it hard to differentiate withdrawal symptoms from those of the underlying disease (Schroeder, in press ). Third, the literature itself is conflicted, with some studies showing symptom exacerbation and others not. The fact that eliminating smoking at mental hospitals has not led to the expected increase in psychiatric symptoms or violence is one bit of indirect evidence supporting the safety of smoking cessation interventions in these patients (Burke, 2006; Levin, 2007; Williams, 2008) . In addition, because the ingredients in tobacco smoke (but not nicotine) can accelerate the metabolism of the P450 hepatic cytochrome enzyme system that breaks down some drugs, stopping smoking can result in increased blood levels of compounds such as phenothiazine, haloperidol, and caffeine. In turn, these increased levels may cause symptoms that are interpreted as nicotine withdrawal, causing patients to resume their smoking.
RELAPSE
Quitting smoking is difficult. Most people who want to quit sometimes try many times before reaching sustainable abstinence (J. O. Prochaska, DiClemente, & Norcross, 1992) . People who are successful have usually experienced relapse first, often because of poor planning. Relapse should be considered as a practice to quit rather than a failure, and many use past quit attempts to learn better ways of quitting. Relapse could also occur if the smoking cessation drugs are discontinued prematurely, taken in too small dosages, used improperly-as often occurs with nicotine-replacement drugs-or not combined with adequate cessation counseling. Although there is suggestion in the literature that smokers with mental illness may be somewhat more prone to relapse, that should not obscure the fact that many such patients are able to quit. Psychiatric nurses and other mental health clinicians should continue to encourage their patients until a successful quit has been accomplished. More available training to boost the confidence of psychiatric nurses' ability to prescribe tobacco cessation treatment should be provided, such as using the Rx for Change curriculum (The Regents of the University of California, 2007).
DOING NOTHING IS THE GREATEST RISK AND IS NO LONGER ACCEPTABLE PRACTICE
Mental health clinicians have spent decades giving excuses for inaction. As clinicians, doing nothing to help patients quit while knowing all the health risks of tobacco is not only unacceptable but also unethical. Clinician advice doubles chances of a smoker's motivation to quit (Fiore et al., 2008) . I commend the American Psychiatric Nurses Association's establishment of its Tobacco Dependence Task Force and national action plan to increase each year by 5% the number of psychiatric nurses who report referring smokers to treatment, and increase each year by 5% the number of psychiatric nurses who provide best clinical practice in tobacco cessation intervention. In October 2008, the APNA Board of Directors approved the task force's position paper, "Psychiatric Nurses as Champions for Smoking Cessation," which highlights the message: Failure to Act on Tobacco Dependence Equals Harm (American Psychiatric Nurses Association, 2008) . It should be required reading for all psychiatric nurses.
SUMMARY AND CONCLUSION
After years of neglect, the mental health treatment community is beginning to rally around the idea that smoking cessation is an integral part of mental health treatment and that achieving health and wellness will require being tobacco free. As of yet there are no citizen advocacy groups supporting this movement-no race for the cure or brown ribbondespite tobacco's heavy toll on the mentally ill. In 2007, a partnership of more than 30 organizations representing mental health clinicians, advocates, and governmental groups formed the National Mental Partnership for Wellness and Smoking Cessation. I am pleased to say that the American Psychiatric Nurses Association has been a robust member of this group, which has pledged to promote smoking cessation in settings where mental illness is treated and to change the culture surrounding smoking and mental illness. Psychiatric nurses should be at the forefront of this new movement, and this issue of JAPNA provides evidence that they are.
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